{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T12:48:59Z","timestamp":1787316539548,"version":"build-2736575974"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T00:00:00Z","timestamp":1773187200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T00:00:00Z","timestamp":1776643200000},"content-version":"vor","delay-in-days":40,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"DOI":"10.1186\/s12967-026-07946-0","type":"journal-article","created":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T14:47:32Z","timestamp":1773240452000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Dynamic biomarker-based machine learning model predicts short-term treatment response in multiple myeloma"],"prefix":"10.1186","volume":"24","author":[{"given":"Yaqin","family":"Xiong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiadai","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingjie","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panpan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yawen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9639-6606","authenticated-orcid":false,"given":"Peng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,11]]},"reference":[{"key":"7946_CR1","doi-asserted-by":"publisher","first-page":"2420","DOI":"10.3324\/haematol.2023.283058","volume":"109","author":"M Engelhardt","year":"2024","unstructured":"Engelhardt M, Kort\u00fcm KM, Goldschmidt H, Merz M. Functional cure and long-term survival in multiple myeloma: how to challenge the previously impossible. Haematologica. 2024;109:2420\u201335. https:\/\/doi.org\/10.3324\/haematol.2023.283058","journal-title":"Haematologica"},{"key":"7946_CR2","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1038\/s41408-024-01115-6","volume":"14","author":"M Mohty","year":"2024","unstructured":"Mohty M, Facon T, Malard F, Harousseau J-L. A roadmap towards improving outcomes in multiple myeloma. Blood Cancer J. 2024;14:135. https:\/\/doi.org\/10.1038\/s41408-024-01115-6.","journal-title":"Blood Cancer J"},{"key":"7946_CR3","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/S0140-6736(21)00135-5","volume":"397","author":"van de Donk Nwcj","year":"2021","unstructured":"van de Donk NWCJ, Pawlyn C, Yong KL. Multiple myeloma. Lancet. 2021;397:410\u201327. https:\/\/doi.org\/10.1016\/S0140-6736(21)00135-5.","journal-title":"Lancet"},{"key":"7946_CR4","doi-asserted-by":"publisher","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","volume":"23","author":"PR Greipp","year":"2005","unstructured":"Greipp PR, San Miguel J, Durie BGM, Crowley JJ, Barlogie B, Blad\u00e9 J, et al. International staging system for multiple myeloma. J Clin Oncol. 2005;23:3412\u201320. https:\/\/doi.org\/10.1200\/JCO.2005.04.242.","journal-title":"J Clin Oncol"},{"key":"7946_CR5","doi-asserted-by":"publisher","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","volume":"33","author":"A Palumbo","year":"2015","unstructured":"Palumbo A, Avet-Loiseau H, Oliva S, Lokhorst HM, Goldschmidt H, Rosinol L, et al. Revised international staging system for multiple myeloma: a report from international myeloma working group. J Clin Oncol. 2015;33:2863\u201369. https:\/\/doi.org\/10.1200\/JCO.2015.61.2267.","journal-title":"J Clin Oncol"},{"key":"7946_CR6","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1200\/JCO.23.01277","volume":"42","author":"F Maura","year":"2024","unstructured":"Maura F, Rajanna AR, Ziccheddu B, Poos AM, Derkach A, Maclachlan K, et al. Genomic classification and individualized prognosis in multiple myeloma. J Clin Oncol. 2024;42:1229\u201340. https:\/\/doi.org\/10.1200\/JCO.23.01277.","journal-title":"J Clin Oncol"},{"key":"7946_CR7","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1038\/nrclinonc.2016.25","volume":"13","author":"DN Khalil","year":"2016","unstructured":"Khalil DN, Smith EL, Brentjens RJ, Wolchok JD. The future of cancer treatment: immunomodulation, CARs and combination immunotherapy. Nat Rev Clin Oncol. 2016;13:273\u201390. https:\/\/doi.org\/10.1038\/nrclinonc.2016.25.","journal-title":"Nat Rev Clin Oncol"},{"key":"7946_CR8","doi-asserted-by":"publisher","first-page":"111640","DOI":"10.1016\/j.intimp.2024.111640","volume":"130","author":"Z Liu","year":"2024","unstructured":"Liu Z, Shen H, Han M, Zhao X, Liu H, Ding K, et al. Immune profiles to predict bortezomib-based treatment response for multiple myeloma patients. Int Immunopharmacol. 2024;130:111640. https:\/\/doi.org\/10.1016\/j.intimp.2024.111640.","journal-title":"Int Immunopharmacol"},{"key":"7946_CR9","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.3390\/diagnostics12092049","volume":"12","author":"M Radzevi\u010dius","year":"2022","unstructured":"Radzevi\u010dius M, Dirs\u0117 V, Klimien\u0117 I, Matuzevi\u010dien\u0117 R, Ku\u010dinskien\u0117 ZA, Pe\u010deli\u016bnas V. Multiple myeloma immunophenotype related to chromosomal abnormalities used in risk assessment. Diagn (Basel). 2022;12:2049. https:\/\/doi.org\/10.3390\/diagnostics12092049.","journal-title":"Diagn (Basel)"},{"key":"7946_CR10","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1038\/s41746-024-01189-3","volume":"7","author":"G Hussain","year":"2024","unstructured":"Hussain G, De Brouwer E, Boiarsky R, Setty S, Gupta N, Liu G, et al. Joint AI-driven event prediction and longitudinal modeling in newly diagnosed and relapsed multiple myeloma. NPJ Digit Med. 2024;7:200. https:\/\/doi.org\/10.1038\/s41746-024-01189-3.","journal-title":"NPJ Digit Med"},{"key":"7946_CR11","doi-asserted-by":"publisher","first-page":"2598","DOI":"10.1158\/1078-0432.CCR-21-3430","volume":"28","author":"C Guerrero","year":"2022","unstructured":"Guerrero C, Puig N, Cedena M-T, Goicoechea I, Perez C, Garc\u00e9s J-J, et al. A machine learning model based on tumor and immune biomarkers to predict undetectable MRD and survival outcomes in multiple myeloma. Clin Cancer Res. 2022;28:2598\u2013609. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-3430.","journal-title":"Clin Cancer Res"},{"key":"7946_CR12","doi-asserted-by":"publisher","first-page":"1716","DOI":"10.1038\/leu.2009.122","volume":"23","author":"A Palumbo","year":"2009","unstructured":"Palumbo A, Sezer O, Kyle R, Miguel JS, Orlowski RZ, Moreau P, et al. International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation. Leukemia. 2009;23:1716\u201330. https:\/\/doi.org\/10.1038\/leu.2009.122.","journal-title":"Leukemia"},{"key":"7946_CR13","doi-asserted-by":"publisher","first-page":"2094","DOI":"10.1038\/leu.2017.29","volume":"31","author":"J Flores-Montero","year":"2017","unstructured":"Flores-Montero J, Sanoja-Flores L, Paiva B, Puig N, Garc\u00eda-S\u00e1nchez O, B\u00f6ttcher S, et al. Next generation flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma. Leukemia. 2017;31:2094\u2013103. https:\/\/doi.org\/10.1038\/leu.2017.29.","journal-title":"Leukemia"},{"key":"7946_CR14","doi-asserted-by":"publisher","first-page":"104440","DOI":"10.1016\/j.jbi.2023.104440","volume":"144","author":"M Kazijevs","year":"2023","unstructured":"Kazijevs M, Samad MD. Deep imputation of missing values in time series health data: a review with benchmarking. J Biomed Inf. 2023;144:104440. https:\/\/doi.org\/10.1016\/j.jbi.2023.104440.","journal-title":"J Biomed Inf"},{"key":"7946_CR15","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1016\/s0895-4356(03)00170-7","volume":"56","author":"JM Engels","year":"2003","unstructured":"Engels JM, Diehr P. Imputation of missing longitudinal data: a comparison of methods. J Clin Epidemiol. 2003;56:968\u201376. https:\/\/doi.org\/10.1016\/s0895-4356(03)00170-7.","journal-title":"J Clin Epidemiol"},{"key":"7946_CR16","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1007\/s10044-015-0492-0","volume":"19","author":"R Maglietta","year":"2016","unstructured":"Maglietta R, Amoroso N, Boccardi M, Bruno S, Chincarini A, Frisoni GB, et al. Automated hippocampal segmentation in 3D MRI using random undersampling with boosting algorithm. Pattern Anal Appl. 2016;19:579\u201391. https:\/\/doi.org\/10.1007\/s10044-015-0492-0.","journal-title":"Pattern Anal Appl"},{"key":"7946_CR17","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1007\/s12026-024-09521-5","volume":"72","author":"P Xu","year":"2024","unstructured":"Xu P, Li Y, Zhuang X, Yue L, Ma Y, Xue W, et al. Changes in immune subsets during chemotherapy as prognosis biomarkers for multiple myeloma patients by longitudinal monitoring. Immunol Res. 2024;72:1185\u201397. https:\/\/doi.org\/10.1007\/s12026-024-09521-5.","journal-title":"Immunol Res"},{"key":"7946_CR18","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.1111\/bcp.15123","volume":"88","author":"H-T Thai","year":"2022","unstructured":"Thai H-T, Gaudel N, Cerou M, Ayral G, Fau J-B, Sebastien B, et al. Joint modelling and simulation of M-protein dynamics and progression-free survival for alternative isatuximab dosing with pomalidomide\/dexamethasone. Br J Clin Pharmacol. 2022;88:2052\u201364. https:\/\/doi.org\/10.1111\/bcp.15123.","journal-title":"Br J Clin Pharmacol"},{"key":"7946_CR19","doi-asserted-by":"publisher","unstructured":"Liu X, Wu F, Ye W, Deng J, Zhang M, Zhang C, et al. Prognostic value of circulating plasma cells detected by flow cytometry in newly diagnosed multiple myeloma patients: a systematic review and meta-analysis. BMJ Open. 2024;14:e071548. https:\/\/doi.org\/10.1136\/bmjopen-2022-071548.","DOI":"10.1136\/bmjopen-2022-071548"},{"key":"7946_CR20","doi-asserted-by":"publisher","first-page":"3120","DOI":"10.1200\/JCO.21.01393","volume":"40","author":"L Bertamini","year":"2022","unstructured":"Bertamini L, Oliva S, Rota-Scalabrini D, Paris L, Mor\u00e8 S, Corradini P, et al. High levels of circulating tumor plasma cells as a key hallmark of aggressive disease in transplant-eligible patients with newly diagnosed multiple myeloma. J Clin Oncol. 2022;40:3120\u201331. https:\/\/doi.org\/10.1200\/JCO.21.01393.","journal-title":"J Clin Oncol"},{"key":"7946_CR21","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/S1470-2045(22)00693-3","volume":"24","author":"R Mina","year":"2023","unstructured":"Mina R, Musto P, Rota-Scalabrini D, Paris L, Gamberi B, Palmas A, et al. Carfilzomib induction, consolidation, and maintenance with or without autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma: pre-planned cytogenetic subgroup analysis of the randomised, phase 2 FORTE trial. Lancet Oncol. 2023;24:64\u201376. https:\/\/doi.org\/10.1016\/S1470-2045(22)00693-3.","journal-title":"The Lancet Oncol"},{"key":"7946_CR22","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1002\/cncr.35056","volume":"130","author":"W Yan","year":"2024","unstructured":"Yan W, Xu J, Fan H, Li L, Cui J, Du C, et al. Early relapse within 18 months is a powerful dynamic predictor for prognosis and could revise static risk distribution in multiple myeloma. Cancer. 2024;130:421\u201332. https:\/\/doi.org\/10.1002\/cncr.35056.","journal-title":"Cancer"},{"key":"7946_CR23","doi-asserted-by":"publisher","first-page":"4547","DOI":"10.1182\/blood-2011-04-345801","volume":"118","author":"M-V Mateos","year":"2011","unstructured":"Mateos M-V, Guti\u00e9rrez NC, Mart\u00edn-Ramos M-L, Paiva B, Montalb\u00e1n M-A, Oriol A, et al. Outcome according to cytogenetic abnormalities and DNA ploidy in myeloma patients receiving short induction with weekly bortezomib followed by maintenance. Blood. 2011;118:4547\u201353. https:\/\/doi.org\/10.1182\/blood-2011-04-345801.","journal-title":"Blood"},{"key":"7946_CR24","doi-asserted-by":"publisher","first-page":"519","DOI":"10.4149\/neo_2021_200814N861","volume":"68","author":"M Stork","year":"2021","unstructured":"Stork M, Bezdekova R, Kralova R, Sandecka V, Adam Z, Krejci M, et al. Prognostic significance of lymphocyte patterns in multiple myeloma patients after autologous transplant. Neoplasma. 2021;68:519\u201327. https:\/\/doi.org\/10.4149\/neo_2021_200814N861.","journal-title":"Neoplasma"},{"key":"7946_CR25","doi-asserted-by":"publisher","first-page":"3443","DOI":"10.1158\/1078-0432.CCR-19-1714","volume":"26","author":"N Alrasheed","year":"2020","unstructured":"Alrasheed N, Lee L, Ghorani E, Henry JY, Conde L, Chin M, et al. Marrow-infiltrating regulatory T cells correlate with the presence of dysfunctional CD4+PD-1+ cells and inferior survival in patients with newly diagnosed multiple myeloma. Clin Cancer Res. 2020;26:3443\u201354. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-1714.","journal-title":"Clin Cancer Res"},{"key":"7946_CR26","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1158\/2326-6066.CIR-15-0055","volume":"4","author":"DJ Chung","year":"2016","unstructured":"Chung DJ, Pronschinske KB, Shyer JA, Sharma S, Leung S, Curran SA, et al. T-cell exhaustion in multiple myeloma relapse after autotransplant: optimal timing of immunotherapy. Cancer Immunol Res. 2016;4:61\u201371. https:\/\/doi.org\/10.1158\/2326-6066.CIR-15-0055.","journal-title":"Cancer Immunol Res"},{"key":"7946_CR27","doi-asserted-by":"publisher","unstructured":"Tan J, Chen S, Huang J, Chen Y, Yang L, Wang C, et al. Increased exhausted CD8+ T cells with programmed death-1, T-cell immunoglobulin and mucin-domain-containing-3 phenotype in patients with multiple myeloma. Asia Pac J Clin Oncol. 2018;14:e266\u201374. https:\/\/doi.org\/10.1111\/ajco.13033.","DOI":"10.1111\/ajco.13033"},{"key":"7946_CR28","doi-asserted-by":"publisher","first-page":"17231","DOI":"10.3390\/ijms242417231","volume":"24","author":"A Edri","year":"2023","unstructured":"Edri A, Ben-Haim N, Hailu A, Brycman N, Berhani-Zipori O, Rifman J, et al. Nicotinamide-expanded allogeneic natural killer cells with CD38 deletion, expressing an enhanced CD38 chimeric antigen receptor, target multiple myeloma cells. Int J Mol Sci. 2023;24:17231. https:\/\/doi.org\/10.3390\/ijms242417231.","journal-title":"Int J Mol Sci"},{"key":"7946_CR29","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1186\/s40164-024-00578-4","volume":"13","author":"K Bisht","year":"2024","unstructured":"Bisht K, Merino A, Igarashi R, Gauthier L, Chiron M, Desjonqueres A, et al. Natural killer cell biology and therapy in multiple myeloma: challenges and opportunities. Exp Hematol Oncol. 2024;13:114. https:\/\/doi.org\/10.1186\/s40164-024-00578-4.","journal-title":"Exp Hematol Oncol"},{"key":"7946_CR30","doi-asserted-by":"publisher","first-page":"153567","DOI":"10.1016\/j.prp.2021.153567","volume":"225","author":"E Koumpis","year":"2021","unstructured":"Koumpis E, Tassi I, Malea T, Papathanasiou K, Papakonstantinou I, Serpanou A, et al. CD56 expression in multiple myeloma: correlation with poor prognostic markers but no effect on outcome. Pathol Res Pract. 2021;225:153567. https:\/\/doi.org\/10.1016\/j.prp.2021.153567.","journal-title":"Pathol Res Pract"},{"key":"7946_CR31","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1111\/bjh.12563","volume":"163","author":"R Hajek","year":"2013","unstructured":"Hajek R, Okubote SA, Svachova H. Myeloma stem cell concepts, heterogeneity and plasticity of multiple myeloma. Br J Haematol. 2013;163:551\u201364. https:\/\/doi.org\/10.1111\/bjh.12563.","journal-title":"Br J Haematol"},{"key":"7946_CR32","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1182\/blood-2012-06-436220","volume":"121","author":"A Chaidos","year":"2013","unstructured":"Chaidos A, Barnes CP, Cowan G, May PC, Melo V, Hatjiharissi E, et al. Clinical drug resistance linked to interconvertible phenotypic and functional states of tumor-propagating cells in multiple myeloma. Blood. 2013;121:318\u201328. https:\/\/doi.org\/10.1182\/blood-2012-06-436220.","journal-title":"Blood"},{"key":"7946_CR33","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.3324\/haematol.2015.138826","volume":"101","author":"HE Johnsen","year":"2016","unstructured":"Johnsen HE, B\u00f8gsted M, Schmitz A, B\u00f8dker JS, El-Galaly TC, Johansen P, et al. The myeloma stem cell concept, revisited: from phenomenology to operational terms. Haematologica. 2016;101:1451\u201359. https:\/\/doi.org\/10.3324\/haematol.2015.138826.","journal-title":"Haematologica"},{"key":"7946_CR34","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1158\/1541-7786.MCR-21-0828","volume":"20","author":"F Cottini","year":"2022","unstructured":"Cottini F, Rodriguez J, Hughes T, Sharma N, Guo L, Lozanski G, et al. Redefining CD56 as a biomarker and therapeutic target in multiple myeloma. Mol Cancer Res. 2022;20:1083\u201395. https:\/\/doi.org\/10.1158\/1541-7786.MCR-21-0828.","journal-title":"Mol Cancer Res"},{"key":"7946_CR35","doi-asserted-by":"publisher","first-page":"5002","DOI":"10.3390\/ijms21145002","volume":"21","author":"S Akhtar","year":"2020","unstructured":"Akhtar S, Ali TA, Faiyaz A, Khan OS, Raza SS, Kulinski M, et al. Cytokine-mediated dysregulation of signaling pathways in the pathogenesis of multiple myeloma. Int J Mol Sci. 2020;21:5002. https:\/\/doi.org\/10.3390\/ijms21145002.","journal-title":"Int J Mol Sci"},{"key":"7946_CR36","doi-asserted-by":"publisher","first-page":"155271","DOI":"10.1016\/j.cyto.2020.155271","volume":"136","author":"S Jasrotia","year":"2020","unstructured":"Jasrotia S, Gupta R, Sharma A, Halder A, Kumar L. Cytokine profile in multiple myeloma. Cytokine. 2020;136:155271. https:\/\/doi.org\/10.1016\/j.cyto.2020.155271.","journal-title":"Cytokine"},{"key":"7946_CR37","doi-asserted-by":"publisher","first-page":"2440","DOI":"10.1002\/cncr.11072","volume":"97","author":"VM Lauta","year":"2003","unstructured":"Lauta VM. A review of the cytokine network in multiple myeloma: diagnostic, prognostic, and therapeutic implications. Cancer. 2003;97:2440\u201352. https:\/\/doi.org\/10.1002\/cncr.11072.","journal-title":"Cancer"},{"key":"7946_CR38","doi-asserted-by":"publisher","first-page":"10396","DOI":"10.1038\/s41467-024-54543-0","volume":"15","author":"R Lutz","year":"2024","unstructured":"Lutz R, Gr\u00fcnschl\u00e4ger F, Simon M, Awwad MHS, Bauer M, Yousefian S, et al. Multiple myeloma long-term survivors exhibit sustained immune alterations decades after first-line therapy. Nat Commun. 2024;15:10396. https:\/\/doi.org\/10.1038\/s41467-024-54543-0.","journal-title":"Nat Commun"},{"key":"7946_CR39","doi-asserted-by":"publisher","first-page":"5134","DOI":"10.1182\/bloodadvances.2025016829","volume":"9","author":"K Kasomva","year":"2025","unstructured":"Kasomva K, Yadav K, Janz S, Dhakal B, Rao S. Molecular and immunological determinants of long-term survival in multiple myeloma. Blood Adv. 2025;9:5134\u201347. https:\/\/doi.org\/10.1182\/bloodadvances.2025016829.","journal-title":"Blood Adv"},{"key":"7946_CR40","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1038\/sj.bmt.1705665","volume":"39","author":"KR Meehan","year":"2007","unstructured":"Meehan KR, Wu J, Bengtson E, Hill J, Ely P, Szczepiorkowski Z, et al. Early recovery of aggressive cytotoxic cells and improved immune resurgence with post-transplant immunotherapy for multiple myeloma. Bone Marrow Transpl. 2007;39:695\u2013703. https:\/\/doi.org\/10.1038\/sj.bmt.1705665.","journal-title":"Bone Marrow Transpl"},{"key":"7946_CR41","doi-asserted-by":"publisher","first-page":"102942","DOI":"10.1016\/j.media.2023.102942","volume":"90","author":"R Pizarro","year":"2023","unstructured":"Pizarro R, Assemlal H-E, Jegathambal SKB, Jubault T, Antel S, Arnold D, et al. Deep learning, data ramping, and uncertainty estimation for detecting artifacts in large, imbalanced databases of MRI images. Med Image Anal. 2023;90:102942. https:\/\/doi.org\/10.1016\/j.media.2023.102942.","journal-title":"Med Image Anal"},{"key":"7946_CR42","doi-asserted-by":"publisher","first-page":"101935","DOI":"10.1016\/j.artmed.2020.101935","volume":"108","author":"L Gao","year":"2020","unstructured":"Gao L, Zhang L, Liu C, Wu S. Handling imbalanced medical image data: a deep-learning-based one-class classification approach. Artif Intell Med. 2020;108:101935. https:\/\/doi.org\/10.1016\/j.artmed.2020.101935.","journal-title":"Artif Intell Med"},{"key":"7946_CR43","doi-asserted-by":"publisher","first-page":"1499530","DOI":"10.3389\/frai.2024.1499530","volume":"7","author":"I Abousaber","year":"2024","unstructured":"Abousaber I, Abdallah HF, El-Ghaish H. Robust predictive framework for diabetes classification using optimized machine learning on imbalanced datasets. Front Artif Intell. 2024;7:1499530. https:\/\/doi.org\/10.3389\/frai.2024.1499530.","journal-title":"Front Artif Intell"},{"key":"7946_CR44","doi-asserted-by":"publisher","unstructured":"Yang X, Wang P, Xu T, Yu C, Yang Y, Liu P. Real-world data analysis on early mortality in Chinese multiple myeloma patients: analysis of 1093 patients during a 15-year period. Hematol Oncol. 2025;43:e70156. https:\/\/doi.org\/10.1002\/hon.70156.","DOI":"10.1002\/hon.70156"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-026-07946-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-07946-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-07946-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T06:42:47Z","timestamp":1776667367000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12967-026-07946-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,11]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["7946"],"URL":"https:\/\/doi.org\/10.1186\/s12967-026-07946-0","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,11]]},"assertion":[{"value":"6 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Committee of Zhongshan Hospital, Fudan University (Approval No. B2023-185\u2009R). Written informed consent was obtained from all participants in accordance with the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"543"}}